Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1

English version České info

Malaria vaccine candidate Apical Membrane Antigen-1 (AMA1) induces protection, but only against parasite strains that are closely related to the vaccine. Overcoming the AMA1 diversity problem will require an understanding of the structural basis of cross-strain invasion inhibition. A vaccine containing four diverse allelic proteins 3D7, FVO, HB3 and W2mef (AMA1 Quadvax or QV) elicited polyclonal rabbit antibodies that similarly inhibited the invasion of four vaccine and 22 non-vaccine strains of P. falciparum. Comparing polyclonal anti-QV with antibodies against a strain-specific, monovalent, 3D7 AMA1 vaccine revealed that QV induced higher levels of broadly inhibitory antibodies which were associated with increased conserved face and domain-3 responses and reduced domain-2 response. Inhibitory monoclonal antibodies (mAb) raised against the QV reacted with a novel cross-reactive epitope at the rim of the hydrophobic trough on domain-1; this epitope mapped to the conserved face of AMA1 and it encompassed the 1e-loop. MAbs binding to the 1e-loop region (1B10, 4E8 and 4E11) were ∼10-fold more potent than previously characterized AMA1-inhibitory mAbs and a mode of action of these 1e-loop mAbs was the inhibition of AMA1 binding to its ligand RON2. Unlike the epitope of a previously characterized 3D7-specific mAb, 1F9, the 1e-loop inhibitory epitope was partially conserved across strains. Another novel mAb, 1E10, which bound to domain-3, was broadly inhibitory and it blocked the proteolytic processing of AMA1. By itself mAb 1E10 was weakly inhibitory but it synergized with a previously characterized, strain-transcending mAb, 4G2, which binds close to the hydrophobic trough on the conserved face and inhibits RON2 binding to AMA1. Novel inhibition susceptible regions and epitopes, identified here, can form the basis for improving the antigenic breadth and inhibitory response of AMA1 vaccines. Vaccination with a few diverse antigenic proteins could provide universal coverage by redirecting the immune response towards conserved epitopes.

Vyšlo v časopise: Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1. PLoS Pathog 9(12): e32767. doi:10.1371/journal.ppat.1003840
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003840

Souhrn

Zdroje

1. SachsJ, MalaneyP (2002) The economic and social burden of malaria. Nature 415: 680–685.

2. CromptonPD, MiuraK, TraoreB, KayentaoK, OngoibaA, et al. (2010) In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun 78: 737–745.

3. CromptonPD, PierceSK, MillerLH (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168–4178.

4. ThamWH, HealerJ, CowmanAF (2012) Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol 28: 23–30.

5. RemarqueEJ, FaberBW, KockenCH, ThomasAW (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74–84.

6. TrigliaT, HealerJ, CaruanaSR, HodderAN, AndersRF, et al. (2000) Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 38: 706–718.

7. Mahdi Abdel HamidM, RemarqueEJ, van DuivenvoordeLM, van der WerffN, WalravenV, et al. (2011) Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 6: e20547.

8. DuttaS, SullivanJS, GradyKK, HaynesJD, KomisarJ, et al. (2009) High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 4: e8138.

9. HodderAN, CrewtherPE, AndersRF (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 3286–3294.

10. PolleySD, MwangiT, KockenCH, ThomasAW, DuttaS, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718–728.

11. StanisicDI, RichardsJS, McCallumFJ, MichonP, KingCL, et al. (2009) Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 77: 1165–1174.

12. ColeyAM, ParisiK, MasciantonioR, HoeckJ, CaseyJL, et al. (2006) The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun 74: 2628–2636.

13. CrewtherPE, MatthewML, FleggRH, AndersRF (1996) Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 64: 3310–3317.

14. HealerJ, MurphyV, HodderAN, MasciantonioR, GemmillAW, et al. (2004) Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol 52: 159–168.

15. TheraMA, DoumboOK, CoulibalyD, LaurensMB, OuattaraA, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004–1013.

16. RemarqueEJ, RoestenbergM, YounisS, WalravenV, van der WerffN, et al. (2012) Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS One 7: e38898.

17. DuttaS, LalithaPV, WareLA, BarbosaA, MochJK, et al. (2002) Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 70: 3101–3110.

18. TakalaSL, DrissaC, TheraMA, BatchelorAH, CummingsMP, AnaniasAA, OuattaraA, NiangalyA, DjimdeAA, PloweCV (2009) Extreme Polymorphism in a Vaccine antigen and risk of clinical malaria: Implications for vaccine development. Science Translational Med 1: 10.

19. KennedyMC, WangJ, ZhangY, MilesAP, ChitsazF, et al. (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948–6960.

20. SagaraI, DickoA, EllisRD, FayMP, DiawaraSI, et al. (2009) A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27: 3090–3098.

21. NarumDL, ThomasAW (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 67: 59–68.

22. HowellSA, Withers-MartinezC, KockenCH, ThomasAW, BlackmanMJ (2001) Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem 276: 31311–31320.

23. HowellSA, WellI, FleckSL, KettleboroughC, CollinsCR, et al. (2003) A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage. J Biol Chem 278: 23890–23898.

24. CaoJ, KanekoO, ThongkukiatkulA, TachibanaM, OtsukiH, et al. (2009) Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in Plasmodium falciparum merozoites. Parasitol Int 58: 29–35.

25. TonkinML, RoquesM, LamarqueMH, PugniereM, DouguetD, et al. (2011) Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science 333: 463–467.

26. RichardD, MacRaildCA, RiglarDT, ChanJA, FoleyM, et al. (2010) Interaction between Plasmodium falciparum apical membrane antigen 1 and the rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites. J Biol Chem 285: 14815–14822.

27. BaumJ, CowmanAF (2011) Biochemistry. Revealing a parasite's invasive trick. Science 333: 410–411.

28. DuttaS, LeeSY, BatchelorAH, LanarDE (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104: 12488–12493.

29. ColeyAM, GuptaA, MurphyVJ, BaiT, KimH, et al. (2007) Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog 3: 1308–1319.

30. KockenCH, van der WelAM, DubbeldMA, NarumDL, van de RijkeFM, et al. (1998) Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem 273: 15119–15124.

31. CollinsCR, Withers-MartinezC, BentleyGA, BatchelorAH, ThomasAW, et al. (2007) Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem 282: 7431–7441.

32. BaiT, BeckerM, GuptaA, StrikeP, MurphyVJ, et al. (2005) Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A 102: 12736–12741.

33. PizarroJC, Vulliez-Le NormandB, Chesne-SeckML, CollinsCR, Withers-MartinezC, et al. (2005) Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 308: 408–411.

34. DuttaS, HaynesJD, BarbosaA, WareLA, SnavelyJD, et al. (2005) Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infect Immun 73: 2116–2122.

35. PolleySD, ConwayDJ (2001) Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158: 1505–1512.

36. DuanJ, MuJ, TheraMA, JoyD, Kosakovsky PondSL, et al. (2008) Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A 105: 7857–7862.

37. MiuraK, HerreraR, DioufA, ZhouH, MuJ, et al. (2013) Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun 81: 1491–1501.

38. RemarqueEJ, FaberBW, KockenCH, ThomasAW (2008) A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 76: 2660–2670.

39. KusiKA, RemarqueEJ, RiasatV, WalravenV, ThomasAW, et al. (2011) Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques. Malar J 10: 182.

40. OuattaraA, Takala-HarrisonS, TheraMA, CoulibalyD, NiangalyA, et al. (2013) Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207: 511–519.

41. KusiKA, FaberBW, ThomasAW, RemarqueEJ (2009) Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One 4: e8110.

42. KusiKA, FaberBW, van der EijkM, ThomasAW, KockenCH, et al. (2011) Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits. Malar J 10: 40.

43. DrewDR, HodderAN, WilsonDW, FoleyM, MuellerI, et al. (2012) Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria. PLoS One 7: e51023.

44. HaynesJD, MochJK, SmootDS (2002) Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. Methods Mol Med 72: 535–554.

45. MalkinEM, DiemertDJ, McArthurJH, PerreaultJR, MilesAP, et al. (2005) Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677–3685.

46. PerssonKE, LeeCT, MarshK, BeesonJG (2006) Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 44: 1665–1673.

47. Chesne-SeckML, PizarroJC, Vulliez-Le NormandB, CollinsCR, BlackmanMJ, et al. (2005) Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites. Mol Biochem Parasitol 144: 55–67.

48. CrawfordJ, TonkinML, GrujicO, BoulangerMJ (2010) Structural characterization of apical membrane antigen 1 (AMA1) from Toxoplasma gondii. J Biol Chem 285: 15644–15652.

49. NairM, HindsMG, ColeyAM, HodderAN, FoleyM, et al. (2002) Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J Mol Biol 322: 741–753.

50. NairM, HodderAN, HindsMG, AndersRF, NortonRS (2001) Assignment of 1H, 13C and 15N resonances of domain III of the ectodomain of apical membrane antigen 1 from Plasmodium falciparum. J Biomol NMR 19: 85–86.

51. HodderAN, CrewtherPE, MatthewML, ReidGE, MoritzRL, et al. (1996) The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 271: 29446–29452.

52. CollinsCR, Withers-MartinezC, HackettF, BlackmanMJ (2009) An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog 5: e1000273.

53. WoehlbierU, EppC, HackettF, BlackmanMJ, BujardH (2010) Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion. Malar J 9: 77.

54. HowellSA, HackettF, JongcoAM, Withers-MartinezC, KimK, et al. (2005) Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens. Mol Microbiol 57: 1342–1356.

55. WilliamsAR, DouglasAD, MiuraK, IllingworthJJ, ChoudharyP, et al. (2012) Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog 8: e1002991.

56. BlissCI (1939) The Toxicity of Poisons Applied Jointly. Annals of Applied Biology 26: 25.

57. LalithaPV, WareLA, BarbosaA, DuttaS, MochJK, et al. (2004) Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response. Infect Immun 72: 4464–4470.

58. NtumngiaFB, SchloegelJ, McHenryAM, BarnesSJ, GeorgeMT, et al. (2013) Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. Vaccine 31: 4382–4388.

59. LiGM, ChiuC, WrammertJ, McCauslandM, AndrewsSF, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 109: 9047–9052.

60. PicaN, HaiR, KrammerF, WangTT, MaamaryJ, et al. (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 109: 2573–2578.

61. KrammerF, PicaN, HaiR, TanGS, PaleseP (2012) Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. J Virol 86: 10302–10307.

62. MillerMS, TsibaneT, KrammerF, HaiR, RahmatS, et al. (2012) 1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans. J Infect Dis 207: 98–105.

63. KusiKA, DodooD, BosomprahS, van der EijkM, FaberBW, et al. (2012) Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population. BMC Infect Dis 12: 32.

64. CortesA, MellomboM, MasciantonioR, MurphyVJ, ReederJC, et al. (2005) Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun 73: 422–430.

65. Vulliez-Le NormandB, TonkinML, LamarqueMH, LangerS, HoosS, et al. (2012) Structural and functional insights into the malaria parasite moving junction complex. PLoS Pathog 8: e1002755.

66. MuellerMS, RenardA, BoatoF, VogelD, NaegeliM, et al. (2003) Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun 71: 4749–4758.

67. OlivieriA, CollinsCR, HackettF, Withers-MartinezC, MarshallJ, et al. (2011) Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodies. PLoS Pathog 7: e1002448.

68. Doria-RoseNA, LouderMK, YangZ, O'DellS, NasonM, et al. (2012) HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol 86: 3393–3397.

69. MiuraK, ZhouH, MuratovaOV, OrcuttAC, GiersingB, et al. (2007) In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 75: 5827–5836.

70. FaberBW, YounisS, RemarqueEJ, Rodriguez GarciaR, RiasatV, et al. (2013) Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun 81: 1479–1490.

71. DuttaS, DlugoszLS, ClaytonJW, PoolCD, HaynesJD, et al. (2010) Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect Immun 78: 661–671.

72. KusiKA, FaberBW, RiasatV, ThomasAW, KockenCH, et al. (2010) Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS One 5: e15391.

73. DouglasAD, WilliamsAR, IllingworthJJ, KamuyuG, BiswasS, et al. (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2: 601.

74. PolhemusME, MagillAJ, CummingsJF, KesterKE, OckenhouseCF, et al. (2007) Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25: 4203–4212.

75. SpringMD, CummingsJF, OckenhouseCF, DuttaS, ReidlerR, et al. (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4: e5254.

76. BruderJT, StefaniakME, PattersonNB, ChenP, KonovalovaS, et al. (2010) Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28: 3201–3210.

77. SedegahM, TammingaC, McGrathS, HouseB, GaneshanH, et al. (2011) Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 6: e24586.

78. CoxNJ, SubbaraoK (2000) Global epidemiology of influenza: past and present. Annu Rev Med 51: 407–421.

79. PolleySD, ChokejindachaiW, ConwayDJ (2003) Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics 165: 555–561.

80. YoshiyamaH, MoH, MooreJP, HoDD (1994) Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. J Virol 68: 974–978.

81. MoorePL, GrayES, WibmerCK, BhimanJN, NonyaneM, et al. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18: 1688–1692.

82. BarclayVC, SimD, ChanBH, NellLA, RabaaMA, et al. (2012) The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi. PLoS Biol 10: e1001368.

83. DuncanCJ, DraperSJ (2012) Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg 86: 561–565.

84. PichyangkulS, TongtaweP, Kum-ArbU, YongvanitchitK, GettayacaminM, et al. (2009) Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28: 452–462.

85. WilsonDW, CrabbBS, BeesonJG (2010) Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays. Malar J 9: 152.

86. DuttaS, HaynesJD, MochJK, BarbosaA, LanarDE (2003) Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A 100: 12295–12300.

87. EscalanteAA, GrebertHM, ChaiyarojSC, MagrisM, BiswasS, et al. (2001) Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol 113: 279–287.

88. KockenCH, NarumDL, MassougbodjiA, AyiviB, DubbeldMA, et al. (2000) Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol Biochem Parasitol 109: 147–156.